Article
Oncology
Qiongqiong Su, Zhiping Fan, Fen Huang, Na Xu, Danian Nie, Dongjun Lin, Ziwen Guo, Pengcheng Shi, Zhixiang Wang, Ling Jiang, Jing Sun, Zujun Jiang, Qifa Liu, Li Xuan
Summary: Delaying prophylactic donor lymphocyte infusion (pDLI) to day +90 based on minimal residual disease (MRD) for patients with refractory/relapsed acute leukemia undergoing allo-HSCT could reduce extensive chronic GVHD incidence and improve GVHD-free/relapse-free survival (GRFS) without increasing the risk of leukemia relapse.
FRONTIERS IN ONCOLOGY
(2021)
Letter
Oncology
Sara Di Giusto, Eleonora Toffoletti, Massimiliano Bonifacio, Gianni Binotto, Maria Cristina Miggiano, Elisabetta Calistri, Manuela Stulle, Anna Ermacora, Rossella Stella, Luigi Scaffidi, Fabio D'Amore, Giorgia Scotton, Davide Griguolo, Giovanna De Matteis, Roberta Bertorelle, Mauro Krampera, Gianpietro Semenzato, Renato Fanin, Daniela Damiani, Mario Tiribelli
Summary: In this study, we analyzed the expression of BCR::ABL1 in chronic myeloid leukemia patients who discontinued imatinib or 2nd generation tyrosine kinase inhibitors (2G-TKIs) while in sustained deep molecular response. The results showed that the levels of BCR::ABL1 were higher in patients who lost major molecular response after discontinuation, and this difference became more evident after 2 months.
Article
Oncology
Yan Hui, Yi Li, Xiwen Tong, Lifang Huang, Xia Mao, Liang Huang, Donghua Zhang
Summary: R/R-AML is characterized by high incidence, short survival, and poor prognosis. Factors influencing prognosis include bone marrow blast proportion and achieving complete remission after reinduction chemotherapy. Hematopoietic stem cell transplantation following complete remission can improve prognosis. The DCIA/DCHA regimen shows good efficacy and tolerable adverse reactions, making it a potential bridging regimen for allo-HSCT in R/R-AML.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Biophysics
Christoph Schmid, Myriam Labopin, Nicolaas Schaap, Hendrik Veelken, Arne Brecht, Michael Stadler, Juergen Finke, Frederic Baron, Matthew Collin, Gesine Bug, Per Ljungman, Didier Blaise, Johanna Tischer, Adrian Bloor, Aleksander Kulagin, Sebastian Giebel, Norbert-Claude Gorin, Jordi Esteve, Fabio Ciceri, Bipin Savani, Arnon Nagler, Mohamad Mohty
Summary: This study analyzed 318 acute leukemia patients who received DLI after alloSCT, showing that preemptive DLI was effective in reducing MRD and increasing chimerism, thus improving survival rates for patients.
BONE MARROW TRANSPLANTATION
(2022)
Article
Oncology
Emily Huschart, Holly Miller, Dana Salzberg, Courtney Campbell, Kristen Beebe, Charlotte Schwalbach, Kyrie Magee, Roberta H. Adams, Alexander Ngwube
Summary: Post-HSCT maintenance therapy with azacitidine and prophylactic DLI was shown to be feasible, safe, and well tolerated for high-risk AML patients, achieving a 90% one-year disease free survival rate.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2021)
Article
Oncology
Caroline Hastings, Yichen Chen, Meenakshi Devidas, A. Kim Ritchey, Naomi J. Winick, William L. Carroll, Stephen P. Hunger, Brent L. Wood, Robert B. Marcus, Julio C. Barredo
Summary: The COG AALL02P2 study aimed to maintain outcomes in patients with late iCNS-R using intensified chemotherapy and a decrease in cranial irradiation. Results showed a 3-year event-free survival (EFS) of 64.3% and overall survival (OS) of 79.6%, with a subset of patients experiencing second relapses including the CNS. New approaches are needed to improve outcomes and determine optimal treatment strategies for these patients.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Biophysics
Akshay Sharma, Ying Li, Sujuan Huang, Aimee C. Talleur, Ali Suliman, Amr Qudeimat, Ashok Srinivasan, Ewelina Mamcarz, Renee Madden, Cheng Cheng, Stephen Gottschalk, Brandon M. Triplett
Summary: Disease relapse remains a major cause of treatment failure in patients undergoing alloHCT for high-risk acute leukemias or MDS. Comprehensive data on outcomes post-transplant relapse, especially in pediatric patients, are lacking. The study suggests that receiving a second alloHCT or having a longer interval between alloHCT and relapse may improve overall survival rates.
BONE MARROW TRANSPLANTATION
(2021)
Article
Chemistry, Physical
Andre Grishin, Bruno Berini, Maxime Vallet, Simon Hurand, Florian Maudet, Corinne Sartel, Mathieu Fregnaux, Sophie Nowak, Gaelle Amiri, Said Hassani, Damien Aureau, Vincent Sallet, Valerie Demange, Yves Dumont
Summary: This study focuses on the direct liquid injection Atomic Layer Deposition (ALD) of TiO2 films with thicknesses of a few nanometers. The researchers propose and demonstrate the effectiveness of 2-dimensional (2D) [Ca2Nb3O10]- and [Ti0.865O2]0.54-nanosheets as seeds for the crystallization and epitaxy of ultra-thin TiO2 films. Furthermore, they find that the structure of the 2D nanosheets determines the growth orientation of the epitaxial anatase, providing potential applications in opto-electronics.
APPLIED SURFACE SCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Guadalupe Rosario Fajardo-Orduna, Edgar Ledesma-Martinez, Itzen Aguiniga-Sanchez, Maria de Lourdes Mora-Garcia, Benny Weiss-Steider, Edelmiro Santiago-Osorio
Summary: AML, the most common type of leukemia in older adults, originates from the clonal expansion of undifferentiated hematopoietic progenitor cells. Despite significant advances in understanding the molecular panorama of AML and the development of therapies targeting mutations, drug resistance remains the main obstacle to treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Mareike Rasche, Martin Zimmermann, Emma Steidel, Todd Alonzo, Richard Aplenc, Jean-Pierre Bourquin, Heidrun Boztug, Todd Cooper, Alan S. Gamis, Robert B. Gerbing, Iveta Janotova, Jan-Henning Klusmann, Thomas Lehrnbecher, Nora Muehlegger, Nils V. Neuhoff, Naghmeh Niktoreh, Lucie Sramkova, Jan Stary, Katharina Waack, Christiane Walter, Ursula Creutzig, Michael Dworzak, Gertjan Kaspers, Edward Anders Kolb, Dirk Reinhardt
Summary: This study evaluated survival, response, and prognostic variables following relapse in children with acute myeloid leukemia (AML). Initial high-risk features and early relapse were found to predict post-relapse survival, while full hematopoietic recovery did not necessarily correlate with better survival outcomes. The data suggest the need for post-relapse risk stratification in future studies.
Article
Oncology
Mareike Rasche, Emma Steidel, Martin Zimmermann, Jean-Pierre Bourquin, Heidrun Boztug, Iveta Janotova, E. Anders Kolb, Thomas Lehrnbecher, Nils von Neuhoff, Naghmeh Niktoreh, Nora Muhlegger, Lucie Sramkova, Jan Stary, Christiane Walter, Ursula Creutzig, Michael Dworzak, Dirk Reinhardt
Summary: This study investigates the treatment response, survival rates, and prognostic factors in children with AML following a second relapse. Survivability is low, but possible for patients who experience a late second relapse and undergo intensive chemotherapy followed by HSCT. Early second relapse is associated with poor outcomes, while achieving a third complete remission is crucial for survival, especially for patients undergoing intensive treatment.
Article
Hematology
Sofie Gottschalk Hojfeldt, Kathrine Grell, Jonas Abrahamsson, Bendik Lund, Kim Vettenranta, Olafur G. Jonsson, Thomas L. Frandsen, Benjamin O. Wolthers, Hanne Vibeke Marquart, Goda Vaitkeviciene, Kristi Lepik, Mats Heyman, Kjeld Schmiegelow, Birgitte Klug Albertsen
Summary: Truncation of asparaginase treatment due to toxicity or silent inactivation may increase relapse risk in children with acute lymphoblastic leukemia, highlighting the importance of therapeutic drug monitoring and appropriate adjustment of therapy.
Article
Hematology
Sumit Gupta, Yunfeng Dai, Zhiguo Chen, Lena E. Winestone, David T. Teachey, Kira Bona, Richard Aplenc, Karen R. Rabin, Patrick Zweidler-McKay, Andrew J. Carroll, Nyla A. Heerema, Julie Gastier-Foster, Michael J. Borowitz, Brent L. Wood, Kelly W. Maloney, Leonard A. Mattano, Eric C. Larsen, Anne L. Angiolillo, Michael J. Burke, Wanda L. Salzer, Stuart S. Winter, Patrick A. Brown, Erin M. Guest, Kimberley P. Dunsmore, John A. Kairalla, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Meenakshi Devidas
Summary: The study found racial and ethnic disparities in childhood acute lymphocytic leukemia survival. Disparities were observed in B-cell acute lymphocytic leukemia but not in T-cell acute lymphocytic leukemia. Further research on relapsed patients, access to care, and structural racism is needed to address these disparities.
LANCET HAEMATOLOGY
(2023)
Article
Oncology
Ibrahim Aldoss, Salman Otoukesh, Jianying Zhang, Sally Mokhtari, Dat Ngo, Mona Mojtahedzadeh, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Paul Koller, Brian Ball, Forrest Stewart, Peter Curtin, Andrew Artz, Ryotaro Nakamura, Guido Marcucci, Stephen J. Forman, Anthony S. Stein, Vinod Pullarkat
Summary: Blintumomab shows promising activity in relapsed/refractory acute lymphoblastic leukemia (ALL) patients, but there are risk factors for treatment failure, particularly extramedullary relapse and retention of CD19 expression.
Article
Oncology
Helena Boutzen, Seyed Ali Madani Tonekaboni, Michelle Chan-Seng-Yue, Alex Murison, Naoya Takayama, Nathan Mbong, Elvin Wagenblast, Elias Orouji, Andrea Arruda, Amanda Mitchell, Faiyaz Notta, Mark D. Minden, Mathieu Lupien, Kerstin B. Kaufmann, John E. Dick
Summary: This study developed a patient-derived system called OCI-AML22 to study acute myeloid leukemia (AML) as a model for cancer stem cells (CSC). Through flow sorting and functional analysis, a highly enriched population of leukemia stem cells (LSC) was identified and successfully isolated and expanded in culture. The system also identified a novel non-coding regulatory element and validated its role in LSC stemness through efficient CRISPR editing.